Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular ca...
Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
About this item
Full title
Author / Creator
Publisher
Tokyo: Springer Japan
Journal title
Language
English
Formats
Publication information
Publisher
Tokyo: Springer Japan
Subjects
More information
Scope and Contents
Contents
Background
Lenvatinib demonstrated a treatment effect on overall survival by the statistical confirmation of non-inferiority to sorafenib for the first-line treatment of uHCC. The objective of this study was to evaluate the cost-effectiveness of lenvatinib compared with sorafenib for patients with uHCC in Japan.
Methods
A partitioned-survi...
Alternative Titles
Full title
Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6536477
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6536477
Other Identifiers
ISSN
0944-1174,1435-5922
E-ISSN
1435-5922
DOI
10.1007/s00535-019-01554-0
